V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 310005442 | 310007043 | 1.65 | 64.5 | Curative (C) | 2016-12-24 | 2016-12-25 | Bevacizumab 7.5mg/kg | 02 | N | 310019434 | GEFITINIB |
| 310005443 | 310007043 | null | 103 | null | null | 2017-06-24 | Docetaxel | 2 | null | 310019434 | DOXORUBICIN + IFOSFAMIDE |
| 310005444 | 310011105 | null | 72.7 | null | 2017-06-01 | 2017-06-02 | Carboplatin + Vinorelbine IV &PO D8 | N | null | 310019741 | EPIRUBICIN |
| 310005445 | 310002525 | 1.77 | null | Curative (C) | 2018-06-12 | 2018-06-12 | DABRAFENIB | 2 | null | 310019918 | CAV |
| 310005446 | 310002526 | 1.61 | 90 | Curative (C) | 2018-02-26 | 2018-03-05 | Carboplatin + Liposomal Doxorubicin | N | N | 310020027 | MITOTANE |
| 310005447 | 310002526 | 1.53 | 76 | Curative (C) | null | 2019-04-17 | Azacitidine | N | null | 310020027 | IVE |
| 310005448 | 310002526 | null | 129 | Palliative (P) | 2016-11-03 | 2016-11-18 | Carboplatin + Pemetrexed | 02 | N | 310020027 | MITOMYCIN |
| 310005449 | 310002527 | 1.66 | 82 | Palliative (P) | 1971-12-27 | 2016-08-21 | FLUOROURACIL + IRINOTECAN | N | N | 310020481 | BEP |
| 310005450 | 310002527 | 1.6 | 41 | Adjuvant (A) | 2015-01-10 | 2015-01-11 | PMitCEBO-R | N | N | 310020481 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 310005451 | 310002528 | 1.66 | 69 | null | 2018-02-24 | 2018-03-27 | CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + VINCRISTINE | null | Y | 310020889 | BRENTUXIMAB |
| 310005452 | 310002529 | null | null | Not known (9) | 2016-03-18 | 2016-04-09 | Bevacizumab + CARBOPLATIN + PACLITAXEL | N | N | 310020916 | BLEOMYCIN + CARBOPLATIN + ETOPOSIDE |
| 310005453 | 310002530 | 1.69 | 58 | Palliative (P) | 2017-08-13 | 2017-08-13 | Doxorubicin + Ifosfamide | 02 | N | 310020945 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 310005454 | 310002531 | null | null | Palliative (P) | 2013-11-19 | 2013-12-11 | Erlotinib | null | N | 310021027 | ALEMTUZUMAB |
| 310005455 | 310002531 | 1.68 | null | Curative (C) | 2016-11-21 | 2016-12-19 | Everolimus 10mg | N | N | 310021027 | CAPECITABINE + MITOMYCIN + RT |
| 310005456 | 310002531 | 1.7 | 0 | Palliative (P) | 2017-01-04 | 2017-01-05 | CVP R | N | N | 310021027 | CAPECITABINE + MITOMYCIN |
| 310005457 | 310002531 | 1.75 | 84.5 | null | 2014-11-09 | 2014-11-24 | CETUXIMAB | N | N | 310021027 | CHLVPP |
| 310005458 | 310002532 | null | 99.4 | null | 2018-02-27 | 2018-03-22 | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE | null | N | 310021313 | METHOTREXATE |
| 310005459 | 310002533 | null | 84.7 | Curative (C) | 2018-06-09 | 2018-06-24 | Bevacizumab+Carbo+Gemcitabine | 02 | N | 310021319 | CYCLOPHOSPHAMIDE + GEMCITABINE + RITUXIMAB + VINCRISTINE |
| 310005460 | 310002533 | 1.61 | 78 | Curative (C) | 2013-05-09 | 2013-05-25 | NEOSCOPE TRIAL | 02 | N | 310021319 | DABRAFENIB + TRAMETINIB |
| 310005461 | 310002534 | 1.54 | 84.9 | Palliative (P) | 2018-03-16 | 2018-03-19 | CAPECITABINE + CARBOPLATIN + Cetuximab | 02 | Y | 310021467 | DOXORUBICIN + OLARATUMAB |
| 310005462 | 310002534 | 1.57 | 44.2 | Curative (C) | 2016-07-30 | 2016-10-04 | ICON8B TRIAL | 2 | N | 310021467 | GEFITINIB |
| 310005463 | 310009281 | 1.83 | null | null | 2014-11-09 | 2014-11-09 | CAPECITABINE + MITOMYCIN + RT | 02 | null | 310021589 | CAPECITABINE + GEMCITABINE |
| 310005464 | 310009281 | 1.62 | 62 | Curative (C) | 2017-06-20 | 2017-06-23 | ICON8B TRIAL | 02 | N | 310021589 | CYCLOPHOSPHAMIDE + GEMCITABINE + VINCRISTINE |
| 310005465 | 310009281 | 1.7 | null | Curative (C) | 2016-03-06 | 2015-11-15 | Trastuzumab Subcutaneous | 2 | N | 310021589 | ETOPOSIDE |
| 310005466 | 310002535 | null | 52.6 | Palliative (P) | 2014-06-13 | 2014-06-15 | Cisplatin + Doxorubicin | 02 | N | 310021779 | FEC |
| 310005467 | 310002536 | null | 70 | Neo-adjuvant (N) | 2018-02-26 | 2018-03-01 | Vincristine (weekly) | Y | N | 310021923 | ECHELON-2 TRIAL |
| 310005468 | 310002537 | 1.7 | 0 | Palliative (P) | 2019-05-12 | 2019-05-13 | Bevacizumab + FLUOROURACIL + IRINOTECAN | null | null | 310021957 | METHOTREXATE |
| 310005469 | 310007049 | 1.55 | 6.7 | Curative (C) | 2014-09-27 | 2014-09-27 | Carboplatin + Liposomal Doxorubicin | 02 | N | 310022020 | CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + VINCRISTINE |
| 310005470 | 310007049 | 1.6 | 84.5 | null | 2013-06-26 | 2013-07-09 | METHOTREXATE | N | N | 310022020 | ALEMTUZUMAB |
| 310005471 | 310002538 | 0 | 95 | Palliative (P) | 2016-08-17 | 2016-09-11 | Sunitinib | Y | N | 310022102 | SUNITINIB |
| 310005472 | 310002539 | 1.6 | 48.45 | Palliative (P) | 2015-10-12 | 2015-10-14 | CARBOPLATIN + VINORELBINE | N | N | 310022131 | CISPLATIN + PEMETREXED |
| 310005473 | 310007050 | null | null | Palliative (P) | 2016-09-17 | 2016-09-26 | Sunitinib | 02 | N | 310022160 | CAPECITABINE + MITOMYCIN |
| 310005474 | 310009283 | null | null | Curative (C) | null | 2015-08-27 | Doxorubicin + Ifosfamide | 02 | null | 310022173 | RCEOP |
| 310005475 | 310002540 | 0 | 98 | Disease modification (D) | 2015-11-03 | 2015-11-04 | Cetuximab + Radiotherapy Load | N | N | 310022205 | ENZALUTAMIDE |
| 310005476 | 310002541 | null | 76 | Curative (C) | 2014-10-11 | 2014-10-28 | Chlorambucil | 2 | N | 310022275 | CYCLOPHOSPHAMIDE + LENALIDOMIDE |
| 310005477 | 310002542 | 1.57 | 63 | null | 2017-10-11 | 2017-10-15 | DABRAFENIB + TRAMETINIB | 02 | N | 310022335 | UKALL 2011 |
| 310005478 | 310002543 | null | 125 | Curative (C) | 2015-11-09 | 2015-11-09 | CVD (Neuroendocrine) | 02 | N | 310022402 | OXALIPLATIN + RALTITREXED |
| 310005479 | 310002543 | 1.73 | 61 | Palliative (P) | 2014-07-28 | 2014-07-28 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | Y | N | 310022402 | FLUOROURACIL + STREPTOZOCIN |
| 310005480 | 310002544 | 1.8 | null | Palliative (P) | 2017-02-18 | 2017-03-03 | Capecitabine + Cisplatin + RT | 02 | N | 310022464 | DOXORUBICIN + IFOSFAMIDE |
| 310005481 | 310002545 | null | 85 | Curative (C) | 2016-08-30 | 2016-08-31 | LANREOTIDE | N | N | 310022506 | IRINOTECAN + MDG |
| 310005482 | 310007052 | 1.79 | null | Curative (C) | 2014-05-19 | 2014-05-28 | Erlotinib | N | N | 310022528 | CHLVPP |
| 310005483 | 310009284 | null | 71 | Disease modification (D) | 2013-12-21 | 2013-12-23 | IVAC | N | N | 310022562 | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE |
| 310005484 | 310002546 | 1.67 | 73.4 | Palliative (P) | 2016-03-09 | 2016-03-09 | TEMOZOLOMIDE | 02 | N | 310022570 | CISPLATIN + FLUOROURACIL + RT |
| 310005485 | 310002547 | 1.56 | 49.1 | Palliative (P) | 2014-04-21 | 2014-04-30 | ALEMTUZUMAB (Intravenous) | 2 | N | 310022639 | MELPHALAN |
| 310005486 | 310007053 | null | 90 | Adjuvant (A) | 2014-11-25 | 2014-12-09 | Capecitabine + Cisplatin + RT | 02 | Y | 310022679 | CETUXIMAB + RT |
| 310005487 | 310007053 | 1.68 | null | Palliative (P) | 2018-02-16 | 2018-02-16 | GDP | 02 | N | 310022679 | CHLORAMBUCIL + ETOPOSIDE + LOMUSTINE |
| 310005488 | 310002548 | null | 54 | null | 2015-07-19 | 2015-08-15 | MITOMYCIN | N | N | 310022710 | CETUXIMAB |
| 310005489 | 310002548 | 1.61 | null | Palliative (P) | null | 2019-03-27 | RCEOP | null | N | 310022710 | PAZOPANIB |
| 310005490 | 310002548 | 1.81 | null | Disease modification (D) | 2015-07-15 | 2015-07-15 | CARBOPLATIN + VINORELBINE | 01 | null | 310022710 | DHAP |
| 310005491 | 310002549 | 1.85 | 83.5 | Palliative (P) | 2014-04-21 | 2014-04-22 | ECF | null | N | 310022763 | CVP R |